Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVO in Recurrent CLL/SLL
NCT06967610Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2025
- Primary completion
- Jun 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pirtobrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Bone marrow undetectable Measurable Residual Disease (10-4 sensitivity) at Cycle 13 and Safety and adverse events at 1 year. Started Jul 2025; status: recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06967610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06967610.